Payment overview · 2025
General Payments
$491.49
27 reported records · 10 companies
Healthcare provider profile · identity verified
Timothy James Littmann, MD
Allopathic & Osteopathic Physicians|Family Medicine · DADEVILLE, AL · NPI 1477050680
Verified facts
What the public records show
CMS Open Payments records show Timothy James Littmann, MD received $491.49 in general payments during 2025 across 27 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 33.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trelegy Ellipta by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $164.30 | 33.4% | 11 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $74.57 | 15.2% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $57.18 | 11.6% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $45.55 | 9.3% | 2 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $36.11 | 7.3% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $30.30 | 6.2% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $24.75 | 5.0% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $22.43 | 4.6% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $22.23 | 4.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.07 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $491.49 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $164.30 | 11 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $74.57 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $57.18 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $45.55 | 2 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $36.11 | 2 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $36.11 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $30.30 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $24.75 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $22.43 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $22.23 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.07 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 24 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
24 | 13 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 170 | 59 |
| Gabapentin | Gabapentin | 144 | 43 |
| Atorvastatin Calcium | Atorvastatin Calcium | 118 | 41 |
| Levothyroxine Sodium | Levothyroxine Sodium | 95 | 29 |
| Losartan Potassium | Losartan Potassium | 95 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 91 | 37 |
| Trazodone Hcl | Trazodone Hcl | 84 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 82 | 75 |
| Ozempic | Semaglutide | 73 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 66 | 22 |
| Meloxicam | Meloxicam | 65 | 27 |
| Furosemide | Furosemide | 62 | 29 |
| Metformin Hcl | Metformin Hcl | 62 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 58 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 55 | 27 |
| Prednisone | Prednisone | 54 | 33 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 50 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 47 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 44 | 11 |
| Carvedilol | Carvedilol | 43 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 43 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 34 |
| Eliquis | Apixaban | 41 | 13 |
| Lisinopril | Lisinopril | 39 | 15 |
| Methylprednisolone | Methylprednisolone | 38 | 37 |
| Tramadol Hcl | Tramadol Hcl | 37 | 15 |
| Buspirone Hcl | Buspirone Hcl | 35 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | 16 |
| Potassium Chloride | Potassium Chloride | 35 | 11 |
| Omeprazole | Omeprazole | 34 | 16 |
| Pregabalin | Pregabalin | 31 | suppressed |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 28 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 27 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 25 | 12 |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | 13 |
| Allopurinol | Allopurinol | 23 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 18 |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 18 |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 17 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Simvastatin | Simvastatin | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Famotidine | Famotidine | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | 12 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $491.49 · 27 records | Bayer Healthcare Pharmaceuticals Inc. | ARISTADA, CAPLYTA, FANAPT, INGREZZA, Kerendia, LYBALVI, OTEZLA, REPATHA, REXULTI, TRELEGY ELLIPTA, VRAYLAR, XIFAXAN | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error